• About
  • Partnerships
  • Challenges
  • Awarded Grants
  • Grant Opportunities
  • News

Genetic Fossils Used As Vaccine Targets for HIV

Because HIV infection activates naturally-dormant endogenous retroviruses (ERV) in human cells, Jonah Sacha will target T cells against these ERV antigens. Such targeting to eliminate HIV infected cells could be the basis for new host-directed vaccines. In this project's Phase I research, Sacha and collaborators demonstrated that ERV-specific antibodies are specifically triggered by infection with an exogenous retrovirus like SIV or HIV. In Phase II, Sacha, now at the Oregon Health & Science University in the U.S., will investigate whether ERV-specific antibodies can block transmission of AIDS viruses in animal models, leading to their potential use as a therapeutic and prophylactic vaccine.

More information about Create New Vaccines for Diarrhea, HIV, Malaria, Pneumonia, and Tuberculosis (Round 3)

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.